進行性肺腺癌の非喫煙者におけるLP-300とカルボプラチンおよびペメトレキセドの併用療法の研究

基本情報

NCT ID

NCT05456256

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

90

治験依頼者名

Lantern Pharma Inc.

概要

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)